advertisement
Abstract #76617 Published in IGR 19-3
Subconjunctival minimally invasive glaucoma surgery : Methods and clinical results
Lenzhofer M; Hohensinn M; Strohmaier C; Reitsamer HAOphthalmologe 2018; 115: 381-387
Minimally invasive glaucoma surgery (MIGS) has been developed for all drainage pathways in glaucoma treatment. Besides implants overriding the resistance in the trabecular meshwork (iStent®, iStent Inject® [both Glaukos Germany GmbH, Wiesbaden, Germany], Hydrus Microstent® [Ivantis, Irvine, CA, USA]) and draining to the suprachoroidal space (Cypass Micro Stent® [Alcon Laboratories, Inc., Fort Worth, TX, USA], iStent Supra® [Glaukos Germany GmbH]), surgeons can further drain aqueous humor into the subconjunctival space with a transscleral MIGS implant (XEN45® [Allergan Plc., Dublin, Irland]). The XEN45® is a gelatine tube 6 mm in length, which is implanted ab interno via a small corneal incision through the sclera. Additional aqueous humor is drained from the anterior chamber via the tube and filtered in a filter cushion in order to sink the total drainage resistance. The internal diameter of the lumen of the implant is 45 µm, therefore a passive resistance is present for prevention of postoperative hypotension. The by-passed aqueous humor forms a conjunctival bleb. Although the first study results are promising in terms of efficacy and safety, further studies are necessary before a clear picture of the effectiveness, safety, advantages and disadvantages of the gelatine tube can be drawn.
Forschungsprogramm für Experimentelle Augenheilkunde, Uniklinikum Salzburg, Paracelsus Medizinische Privatuniversität, Muellner Hauptstr. 48, 5020, Salzburg, Österreich.
Full articleClassification:
12.8.2 With tube implant or other drainage devices (Part of: 12 Surgical treatment > 12.8 Filtering surgery)